US 11,938,220 B2
Sustained-release anesthetic compositions and methods of preparation thereof
Keelung Hong, South San Francisco, CA (US); Yun-Long Tseng, Taipei (TW); Chun-Yen Lai, Taipei (TW); Wan-Ni Yu, Taipei (TW); Hao-Wen Kao, Taipei (TW); and Yi-Yu Lin, Taipei (TW)
Assigned to Taiwan Liposome Co., Ltd, Taipei (TW); and TLC Biopharmaceuticals, Inc., South San Francisco, CA (US)
Appl. No. 17/043,920
Filed by TLC Biopharmaceuticals, Inc., South San Franciso, CA (US); and Taiwan Liposome Co., Ltd., Taipei (TW)
PCT Filed Mar. 30, 2019, PCT No. PCT/US2019/025064
§ 371(c)(1), (2) Date Sep. 30, 2020,
PCT Pub. No. WO2019/191731, PCT Pub. Date Oct. 3, 2019.
Claims priority of provisional application 62/650,912, filed on Mar. 30, 2018.
Prior Publication US 2021/0128475 A1, May 6, 2021
Int. Cl. A61K 9/127 (2006.01); A61K 9/00 (2006.01); A61K 31/445 (2006.01); A61K 47/24 (2006.01); A61K 47/28 (2006.01); A61P 23/02 (2006.01)
CPC A61K 9/1277 (2013.01) [A61K 9/0014 (2013.01); A61K 31/445 (2013.01); A61K 47/24 (2013.01); A61K 47/28 (2013.01); A61P 23/02 (2018.01)] 17 Claims
 
1. An anesthetic composition, comprising:
a lipid based complex comprising ropivacaine base and a lipid mixture including at least one phospholipid in the presence of an aqueous buffer at a pH of 5.5 to 8.0, wherein the at least one phospholipid is derived from saturated fatty acids, each fatty acid independently comprising a carbon chain of carbon number no greater than 18;
wherein the lipid based complex has a median diameter of no less than 1 μm, and the molar ratio of ropivacaine base to phospholipid is at least 0.5:1.